Header

UZH-Logo

Maintenance Infos

Transcatheter heart valve interventions: where are we? Where are we going?


Prendergast, Bernard D; Baumgartner, Helmut; Delgado, Victoria; Gérard, Olivier; Haude, Michael; Himmelmann, Anders; et al; Leafstedt, Matthew; Lennartz, Jasmine; Maisano, Francesco; Thomitzek, Karen (2019). Transcatheter heart valve interventions: where are we? Where are we going? European Heart Journal, 40(5):422-440.

Abstract

Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.

Abstract

Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.

Statistics

Citations

Dimensions.ai Metrics
7 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Vascular Surgery
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Heart valve disease Transcatheter aortic valve replacement Aortic valve Mitral valve Tricuspid valve
Language:English
Date:1 February 2019
Deposited On:14 Mar 2019 11:40
Last Modified:27 Oct 2019 06:58
Publisher:Oxford University Press
ISSN:0195-668X
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/eurheartj/ehy668
PubMed ID:30608523

Download

Full text not available from this repository.
View at publisher

Get full-text in a library